USA ● INDIA1

CBCC Group - Journey at glance

1984 Founded by Dr. Ravi Patel with small cancer clinic of 12,000 Sq. ft.

1990 Expanded into a larger facility with several stations

Began to participate in oncology clinical trials with affiliation to UCLA.1995

1996 Renamed clinic to Comprehensive Blood & Cancer Centre (CBCC).

2007 Opened a new 70,000 sq ft cancer centre becoming the largest centre on west coast,USA.

2008 Inaugurated a brand new centre CBCC CyberKnife® Center.

2011 Acquired an HDXT MRI for expanding diagnosis for Breast Cancer.

2015

Started operation in Gujarat, India.

Started operation in other Indian states Chaatisgadh, Madhyapradesh and Andhra Pradesh.

Started operation in Tamilnadu, India.

2012 Acquired Vigbyor Research India to manage India Operation.

www.cbcc.com

2

CBCC Centers in US – Global HQ

Bakersfield, CA Delano, CATempleton, CA

www.cbcc.com

3

CBCC USA details

www.cbcc.com

4

Investigators at CBCC USA Investigator's Name Specialty

Dr Ravi Patel Medical Oncology

Dr Alan Cartmell Medical Oncology

Dr David Kanamori Medical Oncology

Dr Shawn Shambaugh Medical Oncology

Dr Pradip Rustagi Medical Oncology

Dr Kota Chandra Shekar Medical Oncology

Dr Giridhar Gorla Radiation Oncology

Dr Ajay Desai Radiation Oncology

CBCC USA details

www.cbcc.com

5

Annual New Consults

Solid Tumors

Breast 354

Prostate 135

Colorectal 113

Lung 110

GYN 96

Gastric 78

Head & Neck 49

Brain 48

Thyroid 34

Bladder 33

Kidney 20

Testicular 20

Liver 15

Skin Cancer

Basal/Squamous 510

Melanoma 21

Hematologic

Anemia 277

Lymphoma 84

Multiple Myeloma 13

Leukemia 17

CBCC USA details

www.cbcc.com

6

List of Clients:1. Pfizer2. Genentech 3. AstraZeneca 4. Lilly5. Bristol Myers Squib6. Amgen7. Bayer8. ABBVIE 9. Onyx Pharmaceuticals10. Merck

Studies we have participated that were investigational and now are approved. PalbociclibCrizotinib, Tarceva, Avastin,Neupogen, Procrit,Herceptin

PerjetaKadecyla Aloxi EmendRituxan

UCLA Affiliation

CBCC is part of the UCLA Jonsson Comprehensive Cancer Center's Translational Oncology Research

International (TORI) network. CBCC has collaborated in over 100 clinical trials with UCLA. This partnership

allows CBCC and other leading research institutions and health care providers to offer clinical and

research trials beyond the UCLA campus. All types of cancers are included in these important studies.

What this means to our patients is that they have early access to the latest clinical trials without having to

travel. For a comprehensive list of all our active clinical trials please click here.

www.cbcc.com

7

CBCC Hospitals in India

Raipur - Chattisgarh

Indore - Madhyapradesh

Ahmedabad - Gujarat

Trichy - Tamilnadu

Chennai - Tamilnadu

Jadcherla – Andhra Pradesh

www.cbcc.com

8

13/Jan/2016CBCC-VIBGYOR_List of Oncology Sites

9

Apollo CBCC Center Ahmedabad Vamshi CBCC Cancer & General

Hospital, Jadcherla

G Vishwanathan CBCC Cancer

Hospital, Trichy

Dr. Rai CBCC Cancer Center,

Chennai

Sanjeevani CBCC Cancer Hospital,

RaipurCHL CBCC Cancer Hospital, Indore

CBCC Hospitals in India

Infrastructure Details – Site wise/India

10

Center Bed Strength

No of Consultants

Core Department Radiology Pathology

Ahmedabad 93 31 Surgical, Medical, Radiation, HematoOncology and Stem Cell Transplant

In House In House

Raipur 70 7 Surgical, Medical, Radiation & HematoOncology

In House In House

Indore 60 8 Surgical, Medical, Radiation & HematoOncology

In House In House

Chennai 50 6 Surgical, Medical, Radiation & HematoOncology

In House Outsourced

Trichy 50 7 Surgical, Medical, Radiation & HematoOncology

In House In House

Jadcherla 70 6 Surgical, Medical, & Hemato Oncology Outsourced Outsourced

Annual patient turnover at each site/India

11

Center Surgery Chemo Radiation Total

Ahmedabad 800 4,200 780 5,780

Raipur 480 1,440 480 2,400

Indore 840 2,400 840 4,080

Chennai 600 1,440 600 2,640

Trichy 360 1,080 600 2,040

Jadcherla 450 1200 100 1750

Services

Clinical Trial Project Management of Phase II-IV

PK end point studies on patients

Clinical monitoring

Clinical Data Management

Medical Writing and Communication

Pharmacovigilence

Post market Trials of Drugs and Devices

www.cbcc.com

12

Oncology Clinical Trial Capability/Experience

Breast Cancer

Head and Neck Cancer

Lung Cancer

Ovarian Cancer

Pancreatic Cancer

Prostate Cancer

Colon Cancer

Esophageal/Gastric Cancer

www.cbcc.com

13

Experience of PK end point studies

PK End point study of liposomal doxorubicin on ovarian Cancer patients: 46 patients enrolled at

12 sites.

PK End point study of liposomal doxorubicin on ovarian Cancer patients: 30 patients enrolled at

08 sites.

PK End point study of Capecitabin on Metastatic Brest Cancer patients: 54 patients enrolled at 10

sites.

PK End point study of Capecitabin on Metastatic Brest Cancer patients: 46 patients enrolled at 08

sites.

PK End point study of Sunitinib on advanced renal cell carcinoma patients: 60 patients enrolled at

10 sites.

PK End point study of Bortezomib on multiple myeloma patients: 30 patients enrolled at 07 sites.

PK End point study of Imatinib on CML patients: 36 patients enrolled at 06 sites.

www.cbcc.com

14

Why CBCC for PK end point studies

With extensive setup in India and USA, we recruit patients at our own hospital site and not

dependent on the outside investigator sites for the enrolment.

Common SOP and training system at all our hospital sites in India and USA.

Well equipped sites with infrastructure like Continuous ECG monitoring, Automated

centrifuge , Deep freezer, Pharmacy freezers.

Strong documentation system at all sites to archive study documents which is essential for

regulatory audits at site.

Well trained site staff having experience of managing international regulatory audits.

While recruiting patients for one indication we don’t accept another study with same

indication to complete the total recruitment in the shortest possible time.

CTMS softer with unique sponsor login to present continuous study updates to Sponsor

www.cbcc.com

15

Key Differentiator

More than 30 years of rich experience in Clinical trials with core focus on Oncology.

Largest private Cancer Care Provider in North America.

Global outreach to manage complex clinical trials in various locations.

Rich experience of successful trial execution and submission to various regulatory agencies

around the globe.

Very stable top management.

www.cbcc.com

16

THANK YOU

www.cbcc.com

17